tradingkey.logo

GE Healthcare Q4 revenue beats estimates on diagnostics growth

ReutersFeb 4, 2026 11:29 AM


Overview

  • Healthcare technology firm's Q4 revenue grew 7.1%, beating analyst expectations

  • Adjusted EPS for Q4 beat analyst expectations

  • Company announced planned $2.3 bln acquisition of Intelerad


Outlook

  • GE Healthcare forecasts 2026 organic revenue growth of 3.0% to 4.0%

  • Company expects 2026 adjusted EPS between $4.95 and $5.15

  • GE Healthcare anticipates 2026 free cash flow of approximately $1.7 bln


Result Drivers

  • PHARMACEUTICAL DIAGNOSTICS - Revenue growth driven by strong performance in Pharmaceutical Diagnostics, Imaging, and AVS, particularly in U.S. and EMEA

  • TARIFF IMPACT - Tariff expenses and unfavorable mix negatively impacted margins, partially offset by volume and price

  • OPERATIONAL RESILIENCE - Company mitigated gross tariff impacts and demonstrated operational resilience, per CFO Jay Saccaro


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$5.70 bln

$5.61 bln (15 Analysts)

Q4 Adjusted EPS

Beat

$1.44

$1.40 (16 Analysts)

Q4 EPS

$1.29

Q4 Net Income

$589 mln

Q4 Adjusted Free Cash Flow

$1 bln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for GE Healthcare Technologies Inc is $93.00, about 18.1% above its February 3 closing price of $78.78

  • The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nBw61tg6va

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI